The world
of the infinitely small

Venue : Auditoire de l’Institut de Biologie de Lille,

Institut Pasteur de Lille,

1, rue du Prof. Calmette,

F-59019 Lille Cedex, France

November 17, 2021

13h00 – 14h00 :     Registration

14h00 – 15h30 :     Opening session
    Welcome address by Prof. Xavier Nassif, Director General of Institut Pasteur de Lille
    The History of BCG: Camille Locht, France
    BCG and tuberculosis in the world today: Ann Ginsberg, USA
    BCG production, challenges and world-wide supply: Soumya Swaminathan, WHO Geneva, Switzerland

15h30 – 16h00:     Coffee break

16h00 – 18h30:     Session 1: novel vaccine approaches against tuberculosis
    Human immune responses to BCG, towards correlates of protection: Olubukola Idoko, The Gambia
    Revaccination with BCG: Mark Hatherill, South Africa
    Alternative routes of BCG vaccination: iv vaccination, Robert A. Seder, USA

    Alternative routes of BCG vaccination, mucosal vaccination: Frank Verreck, The Netherlands

    VPM1002; a recombinant BCG vaccine against tuberculosis: Stefan Kaufmann, Germany/USA
    MTBVAC an attenuated Mycobacterium tuberculosis vaccine, ready to start clinical efficacy trials, 100 years after the first vaccination with Mycobacterium bovis BCG: Carlos Martin, Spain
18h30 – 20h00:     Cocktail reception with the participation of Sylvain Thénault-Guérin, great-grandson of Camille Guérin.


November 18, 2021

9h00 – 11h30 :     Session 2: Non-specific off-target effects against other infections
    Effect of BCG on overall childhood mortality: Victoria Nankabirwa, Uganda
    The non-specific effects of BCG on heterologous infections: Sarah Prentice, Uganda/UK
    BCG and trained innate immunity: Eva Kaufmann, Canada
    BCG-mediated protection against neonatal sepsis: Nelly Amenyogbe, Australia
    Effect of BCG on immunogenicity of heterologous vaccines: Petra Zimmermann, Switzerland

    Effect of parental BCG priming on the offspring: Christine Stabell Benn, Denmark

11h30 – 14h00:     Walking lunch and Poster viewing

14h00 – 16h00:     Session 3: BCG and COVID-19
    The BRACE project: Nigel Curtis, Australia
    Randomized Clinical trial of BCG vaccination against COVID in the elderly: Henri Werkhoven, Utrecht, The Netherlands
    Impact of COVID on BCG vaccination coverage and paedriatic tuberculosis mortality: Richard White, UK
    10- to 15-min presentations selected from the abstracts

16h00 – 16h30:     Coffee break

16h30 – 17h30:     The future of BCG vaccination, should BCG be re-introduced because of its off-target effects: round-table discussion, chaired by Ann Ginsberg, USA

17h30 – 18h30:    10- to 15-min presentations selected from the abstracts

19h00 - ???    Conference dinner at Hermitage Gantois


November 19, 2021

9h00 - 10h30 :     Session 4: BCG and cancer
    BCG and bladder cancer immunotherapy: Molly Ingersoll, France
    BCG as a therapy for inoperable cutaneous metastatic melanoma: Fabiana Kömming Seixas, Brazil [PENDING]
    Recombinant BCG for cancer treatment: William Bishai, USA

10h30 – 11h00:     Coffee break

11h00 – 12h30:     Session 5: BCG and inflammatory & auto-immune diseases
    BCG vaccine in neuroinflammation: from demyelinating to neurodegenerative diseaeses: Giovanni Ristori, Italy
    BCG therapy in bladder cancer is associated with a significant reduced risk of Alzheimer’s disease and Parkinson’s disease: Hervé Bercovier, Israel.
    BCG and allergy: Laure Pittet, Switzerland

12h30 – 13h00:     Closing lecture: Stanley Plotkin, USA [PENDING]

13h00 - ??:     Lunch and farewell